<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Vaxess Technologies — Prospect Detail</title>
  <link rel="stylesheet" href="styles.css">
</head>
<body>
<header class="site-header"><h1>Prospect Detail</h1></header>
<div class="container">
  <a href="index.html" class="back-link">&larr; Back to All Prospects</a>
  <div class="detail-header">
    <span class="badge health" style="font-size:.8rem;">Digital Health</span>
    <h1>97. Vaxess Technologies</h1>
    <p class="meta">Thermostable Vaccine Delivery</p>
  </div>
  <div class="caution-box"><strong>Note:</strong> This company was sourced from President's Innovation Challenge. Per assignment guidelines, i-Labs sources are typically excluded but included here for reference.</div>
  <div class="section"><h3>1. Startup Name</h3><p><strong>Vaxess Technologies</strong></p></div>
  <div class="section"><h3>2. Founder Contact</h3><p><strong>Harvard PIC Winner</strong></p><p>Harvard Innovation Labs / President's Innovation Challenge</p><p>Founded on Wyss Institute silk protein technology</p></div>
  <div class="section"><h3>3. Product Overview</h3><p>Vaxess Technologies develops thermostable vaccine delivery using silk protein technology. The MIMIX platform uses silk-based patches to deliver vaccines without refrigeration, potentially revolutionizing vaccine distribution in developing countries where cold chain logistics are challenging.</p></div>
  <div class="section"><h3>4. Funding Stage</h3><p><strong>Series A</strong> — Raised $8M+ to advance vaccine patch development.</p></div>
  <div class="section"><h3>5. How I Found the Company</h3><p>Discovered through President's Innovation Challenge winners and vaccine innovation coverage.</p></div>
  <div class="strengths-weaknesses">
    <div class="section"><h3>Strengths</h3><ul><li><strong>Global health impact:</strong> Cold chain elimination could save millions of vaccine doses.</li><li><strong>Novel technology:</strong> Silk protein platform has unique stability properties.</li></ul></div>
    <div class="section"><h3>Weaknesses</h3><ul><li><strong>Clinical validation:</strong> Must prove patch delivery is as effective as injection.</li><li><strong>Pharma partnerships:</strong> Need vaccine manufacturers to adopt platform.</li></ul></div>
  </div>
  <div class="section"><h3>7. Five Questions for the Team</h3><ol class="questions-list"><li>What vaccines have you validated with your silk protein platform?</li><li>What is the shelf life without refrigeration?</li><li>How do you partner with vaccine manufacturers?</li><li>What is your regulatory pathway for vaccine delivery devices?</li><li>Which global health organizations are you working with?</li></ol></div>
  <a href="index.html" class="back-link">&larr; Back to All Prospects</a>
</div>
</body>
</html>
